Accelerate Diagnostics (NASDAQ:AXDX) issued its earnings results on Thursday. The medical research company reported ($0.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.01, Fidelity Earnings reports. The business had revenue of $2.27 million for the quarter, compared to analyst estimates of $3.15 million. Accelerate Diagnostics had a negative net margin of 1,293.91% and a negative return on equity of 170.47%.
AXDX stock traded down $0.20 during trading on Friday, hitting $15.39. 512,100 shares of the company’s stock traded hands, compared to its average volume of 246,010. The firm has a market capitalization of $886.97 million, a P/E ratio of -9.50 and a beta of 2.72. The business has a fifty day simple moving average of $17.85 and a two-hundred day simple moving average of $19.06. Accelerate Diagnostics has a 1 year low of $10.23 and a 1 year high of $24.00. The company has a quick ratio of 18.89, a current ratio of 19.99 and a debt-to-equity ratio of 4.81.
A number of equities analysts have recently commented on the stock. ValuEngine lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday. BidaskClub lowered shares of Accelerate Diagnostics from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 2nd. Piper Jaffray Companies reduced their target price on shares of Accelerate Diagnostics from $22.00 to $19.00 and set a “positive” rating on the stock in a research report on Friday, August 9th. Finally, JPMorgan Chase & Co. lowered shares of Accelerate Diagnostics from a “neutral” rating to an “underweight” rating and set a $16.00 target price on the stock. in a research report on Friday, September 27th. Three analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. Accelerate Diagnostics has an average rating of “Hold” and an average target price of $18.67.
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.
Read More: Dogs of the Dow
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.